SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab

 SLIDE KIT   12/2021

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma 

Rating

Rate this resource